Article
Affinity-matured recombinant immunotoxin targeting gangliosides 3'-isoLM1 and 3',6'-isoLD1 on malignant gliomas.
mAbs - 1 Jan 2000
Piao Hailan, Kuan Chien-Tsun, Chandramohan Vidya, Keir Stephen T, Pegram Charles N, Bao Xuhui, Månsson Jan-Eric, Pastan Ira H, Bigner Darell D
Abstract excerpt
About 60 percent of glioblastomas highly express the gangliosides 3'-isoLM1 and 3',6'-isoLD1 on the cell surface, providing ideal targets for brain tumor immunotherapy. A novel recombinant immunotoxin, DmAb14m-(scFv)-PE38KDEL (DmAb14m-IT), specific for the gangliosides 3'-isoLM1 and 3',6'-isoLD1, was constructed with improved affinity and increased cytotoxicity for immunotherapeutic targeting of glioblastoma. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.